In the ninth episode of the GHAPP & RhAPP Biosimilar Podcast Series, host Amanda Mixon, PA-C, welcomes guest Daric Mueller, PA-C, for an engaging discussion on the practical use of biosimilars in rheumatology APP practice. As biosimilars continue to reshape treatment options for rheumatic diseases, understanding their application in clinical settings is essential for advanced practice providers (APPs) looking to optimize patient care.
The conversation kicks off with an exploration of the American College of Rheumatology (ACR) White Paper on Biosimilars, which serves as a guiding document for rheumatology providers navigating the evolving landscape of biologic therapy. Amanda and Daric break down key takeaways from the white paper, including the rigorous standards biosimilars must meet to gain FDA approval, their comparable efficacy and safety profiles to reference biologics, and the regulatory distinctions between biosimilars and interchangeable biosimilars.
A major focus of the discussion revolves around the clinical use of biosimilars in rheumatic diseases. With biosimilars now available for conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, APPs must stay informed on their role in treatment algorithms. Daric shares insights on selecting the right biosimilar for individual patients, the impact of payer-driven formularies, and considerations for switching stable patients from a reference biologic to a biosimilar.
One of the most critical aspects of biosimilar adoption is implementation in rheumatology practice. Amanda and Daric outline strategies for integrating biosimilars into treatment plans, addressing common concerns from patients and providers. They emphasize the importance of patient education, transparency in communication about biosimilar safety and efficacy, and the need for ongoing provider engagement with payers to ensure seamless access. They also discuss practical steps for navigating insurance-mandated biosimilar substitutions, prior authorization processes, and formulary restrictions.
Throughout the episode, Daric highlights real-world experiences with biosimilars in clinical practice, detailing how increased affordability and access have positively impacted patient outcomes. He also discusses challenges, such as overcoming patient hesitancy and provider resistance to change, and offers solutions to streamline the transition process.
This episode provides a comprehensive guide for rheumatology APPs looking to integrate biosimilars effectively into their practice. Whether you’re considering biosimilars for new patients or transitioning existing patients, Amanda and Daric’s insights will help you feel confident in navigating the biosimilar landscape.
Visit the RhAPP website or explore additional educational content on the RhAPP ACE App.
Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval
